Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium

LINCOLN, Mass., Jan. 24, 2017 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in a Keystone Symposium on Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies.  Anna Katharina Wilkins, PhD, Senior Scientist at Applied BioMath will present a poster titled "Computational exploration of mechanistic determinants of antibody drug-conjugate pharmacokinetics using quantitative systems pharmacology modeling strategies."  In addition, Jennifer Park, PhD, Director of Business Development at Applied BioMath will present a poster titled "Quantitative systems pharmacology and immunotherapy:  accelerating lead generation and optimization of a PD-1 x TIM-3 biotherapeutic in immuno-oncology."

"Applied BioMath is committed to pushing the envelope in the field of quantitative systems pharmacology as well as educating scientists about the value of incorporating such technology into their drug research and development," said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath.  "This Keystone Symposium provides an ideal environment for us to present our cutting-edge research to scientists from leading industry and academic institutions as well as regulatory agencies."        

About Applied BioMath

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.   Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.   Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press contact: Kristen Zannella [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/applied-biomath-llc-presents-work-in-immuno-oncology-and-antibody-drug-conjugates-at-keystone-symposium-300396010.html

SOURCE Applied BioMath